Infliximab (Remicade) as an adjunct to pegylated-interferon alpha-2b and ribavirin in the treatment of hepatitis C virus infection.

Trial Profile

Infliximab (Remicade) as an adjunct to pegylated-interferon alpha-2b and ribavirin in the treatment of hepatitis C virus infection.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Infliximab (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms PARTNER
  • Most Recent Events

    • 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Mar 2011 Planned End Date changed from 1 Sep 2011 to 1 May 2012 as reported by ClinicalTrials.gov.
    • 28 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top